In a report released today, Michael Petusky from Barrington maintained a Buy rating on Anika Therapeutics Inc (NASDAQ: ANIK), with a price target of $49. The company’s shares closed yesterday at $39.51.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 12.5% and a 57.3% success rate. Petusky covers the Services sector, focusing on stocks such as US Physical Therapy, Tivity Health Inc, and BioScrip Inc.
Anika Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $48.
Based on Anika Therapeutics Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $7.6 million. In comparison, last year the company had a net profit of $6.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.